We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,800
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Chronic Rhinosinusitis and Olfactory Dysfunction

Huart Caroline¹,², Franceschi Daniel³ and Rombaux Philippe¹,²

¹Department of Otorhinolaryngology, Cliniques Universitaires Saint-Luc, Brussels, ²Institute of Neuroscience, Université Catholique de Louvain, Brussels, ³Department of Otorhinolaryngology, Clinique Sainte-Elisabeth, Brussels, Belgium

1. Introduction

Chronic rhinosinusitis (CRS) is defined, according to the European Position Paper on Rhinosinusitis and Nasal Polyps (Fokkens et al., 2007), as “presence of two or more symptoms one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip) +/- facial pain/pressure +/- reduction or loss of smell for >12 weeks”. Olfactory disorder thus appears to be one of the diagnosis criteria for CRS with or without nasal polyposis, underlining the importance of this specific symptom among patients with CRS. Inversely, CRS appears to be the most common cause of olfactory dysfunction in patients presenting to smell evaluating centers and account for 14-30% of the cases (Holbrook and Leopold, 2006; Landis et al., 2004; Mott and Leopold, 1991; Raviv and Kern 2004; Seiden and Duncan, 2001). What underlines the intimate connection between CRS and olfactory dysfunction.

Several studies have shown that the quality of life is severely impaired in patients suffering from olfactory disorders (Frasnelli and Hummel, 2005; Neuland et al., 2011). It is thus important to detect this symptom and to provide an optimal treatment to patients. Nowadays, we have medical and surgical treatments that may relieve patients but these results are still hazardous.

Good management and good support to patients highly depend on a good knowledge of this entity. We will thus review important issues about CRS and olfactory dysfunction, beginning with generalities about olfactory dysfunction, to continue with pathophysiology of this entity, assessment of olfactory function in patients, the contribution of imaging and finally effects of current treatments on olfactory function.

2. Olfactory dysfunction

The incidence of olfactory dysfunction among the population is still a matter of debate. Authors report an incidence of 1-3% of dysfunction among population (Hoffman et al., 1998; Murphy et al., 2002). Nevertheless a recent study by Landis et al. (2004) reported higher values of olfactory dysfunction among population without sinonasal complaints, with a rate
of 4.7% of anosmia and 16% of hyposmia. The most common causes of olfactory disorder are CRS, upper respiratory tract infection and head trauma. It is also mandatory to note that in a significant number of cases the cause of olfactory dysfunction remains unknown, even after investigations. (Table 1)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Rhinosinusitis</td>
</tr>
<tr>
<td>2</td>
<td>Post upper respiratory tract infection</td>
</tr>
<tr>
<td>3</td>
<td>Idiopathic</td>
</tr>
<tr>
<td>4</td>
<td>Post traumatic</td>
</tr>
<tr>
<td>5</td>
<td>Iatrogen</td>
</tr>
<tr>
<td>6</td>
<td>Toxic</td>
</tr>
<tr>
<td>7</td>
<td>Congenital</td>
</tr>
<tr>
<td>8</td>
<td>Miscellaneous</td>
</tr>
</tbody>
</table>

Table 1. Etiologies of olfactory dysfunction listed in descending order. Rhinosinusitis appears to be the most important cause of olfactory dysfunction in the general population.

In the literature, CRS is described as the most common cause of olfactory dysfunction, accounting for 14-30% of cases (Holbrook and Leopold 2006; Mott and Leopold, 1991; Raviv and Kern 2004; Seiden and Duncan, 2001). Inversely, olfactory impairment is a common symptom affecting 61-83% of patients with CRS (Bhattacharyya, 2003; Litvak et al., 2008; Orlandi and Terrell, 2002; Soler et al., 2008). Nevertheless up to one quarter of patients with CRS are unaware of their decreased olfactory abilities, probably because the olfactory dysfunction in CRS develops slowly and in consequence only a few patients note this disorder (Nordin et al., 1995). Psychophysical tests results show that patients with CRS have quantitative disorders, between hyposmia and anosmia (Holbrook and Leopold 2006; Mott and Leopold, 1991; Raviv and Kern 2004; Seiden and Duncan, 2001; Welge-Luessen, 2009) and may report fluctuating symptoms (Apter et al., 1999). Also it is widely known that patients with CRS with polyps have a higher incidence of smell symptoms and anosmia than patients with CRS without polyps (Hellings and Rombaux, 2009).

Some studies have described that the severity of quantitative disorders is related to the importance of the sinonasal disease (Litvack et al., 2008, 2009a). Indeed, the mean endoscopy score and the mean CT score are significantly higher (more abnormal) in patients with hyposmia and anosmia than in patients with normosmia (Litvack et al., 2009a). Also, the opacification of the olfactory cleft on the CT scan seems to have a negative correlation with the olfactory function (Chang et al., 2009).

Patients with CRS not only report quantitative olfactory dysfunction but also qualitative dysfunction such as parosmia and phantosmia. However, these symptoms seem less frequent when related to sinonasal disease than to other etiologies (i.e. post-infectious, post traumatic) and Reden et al. (2007) reported incidence of parosmia and phantosmia in patients with CRS of 28% and 7%, respectively.
It is also mandatory to note that the quality of life of patients suffering from olfactory disorders is severely impaired. Indeed it has been described that patients with olfactory disorders not only complain about daily life problems (cooking, detection of potentially dangerous odors) (Temmel et al., 2002) but also have a higher prevalence of mild to severe depression compared to the general population (Deems et al., 1991). Using questionnaire of olfactory disorder and psychometric tests some authors reported that patients suffering from quantitative olfactory impairment significantly more complaints that patients with normosmia and this was even more important if they had associated parosmia (Frasnelli and Hummel, 2005; Neuland et al., 2011). Finally, since patients reporting an improvement of their olfactory abilities have a better quality of life than patients reporting no improvement (Miwa et al., 2001); it is essential to investigate about the etiology of olfactory dysfunction in instance to provide an optimal treatment to the patients. Particularly in cases of chronic rhinosinusitis, different treatments are available and improve olfactory function. They will be discussed later.

3. Pathophysiology

Traditionally, olfactory dysfunction in CRS is explained by a conductive olfactory loss, caused by swollen or hypertrophic nasal mucosa or nasal polyps, inducing an impaired access of odorants to the olfactory cleft. But clinical studies have failed to prove this hypothesis, as there is only little correlation between nasal resistance and the degree of olfactory dysfunction (Doty and Frye, 1989; Cowart et al., 1992). In addition, results of surgical therapy, although improving the nasal patency, are sometimes uncertain when considering the olfactory dysfunction.

Some studies have shown that the olfactory disturbance might also be explained by inflammatory process in the olfactory cleft (Konstantinidis et al., 2007). Indeed, biopsies of the olfactory neuroepithelium in patients suffering from CRS revealed inflammatory changes in the nasal mucosa and apoptotic pathological changes, including the olfactory receptor neurons and olfactory supporting cells (Hellings and Rombaux, 2009; Naessen, 1971). Also, inflammatory cells release inflammatory mediators, which are known to trigger hypersecretion in respiratory and Bowman’s glands (Hellings and Rombaux, 2009; Getchell and Mellert, 1991; Downey et al., 1996). Hypersecretion of Bowman’s gland is thought to alter the ion concentrations of olfactory mucus, affecting the olfactory transduction process (Kern et al., 1997; Joshi et al., 1987). In addition, cytokines and mediators, particularly those released by eosinophils, may be toxic to olfactory receptor neurons (Apter et al., 1992; Nakashima et al, 1985), and the degree of inflammation changes in the neuropithelium is related to the severity of olfactory dysfunction (Kern, 2000)

Patients with nasal polyps show a higher incidence of olfactory disturbances and a higher incidence of anosmia than patients with CRS without polyps. This more severe symptomatology may be explained by the conductive olfactory loss induced by polyps but also by degenerative changes associated with recurrent infections, scaring, chronic nasal medication, exotoxins and enhanced secretion of cytokines from Staphylococcus Aureus infection and neurotoxic cytokines released by a huge eosinophilic population (Bernstein et al., 2011; Holcomb et al., 1996; Joshi et al., 1987; Litvack et al., 2008; Vento et al., 2001; Wang et al., 2010).
4. Assessment of olfactory function

Assessment of olfactory function should be considered in the clinical evaluation of patients suffering from chronic rhinosinusitis and complaining of olfactory disorders. Not only this evaluation allows detecting and quantifying olfactory disorders but also it is useful to objectively and reproducibly assess the efficacy of a treatment on olfactory function.

Odorants can reach the olfactory cleft both orthonasally (from the nostrils to the olfactory cleft) and retronasally (from the oral cavity to the olfactory cleft).

The most widely used tests for the evaluation of the orthonasal function are the Sniffin’ Sticks test (Hummel et al., 2007; Burghart Medical Technology, Wedel, Germany) and the UPSIT (University of Pennsylvania smell identification test) (Doty et al., 1984). These semi-objective tests have the advantage of being easy to implement and of having been validated in multicenter studies. The Sniffin’ Sticks test consists in felt-tip pens that are presented in front of the nose of the patient. It encompasses three different approaches. First the odor threshold \((T)\) assessment; second the odor discrimination \((D)\) and third odor identification \((I)\). To judge the olfactory function, these three results are added together to provide a total TDI score. The UPSIT test 40 items. It encompasses fours “scratch and sniff” booklets that can be self administered or applied by a third party. Odorants are embedded in microcapsules positioned on brown strips at the bottom of the page of booklets. The stimuli are released by scratching the strip with a pencil and subjects have to choice one of the four proposed descriptors that best corresponds to odor (Doty et al., 1984; Tourbier and Doty, 2007). These two tests are forced choice, what mean that the subject must provide a response even if no odor is perceived.

Retronasal olfactory performances can also be evaluated following a standardized method using a row of 20 items. Powder substances are applied using squeezable plastic vials in the middle of the tongue inside the oral cavity. Each substance is identified by means of a forced-choice procedure between 4 items. (Heilmann et al., 2002)

Nevertheless these tests have the disadvantage to be semi-objective and might be biased by the patient’s response.

The objective evaluation of the olfactory function relies on event-related potentials technique. This technique is based on the fact that brief olfactory stimulus elicit transient changes in the ongoing electrographic activity. To evaluate olfactory function a pure odorant substance (i.e. 2-phenylethanol) is delivered in the nose of the patients (Kobal and Hummel, 1988). Since the magnitude of the transient olfactory-induced EEG deflection is much smaller than the magnitude of the background EEG, the event is repeated several times and recorded responses are the added and averaged into a single waveform to increase the signal to noise ratio. The bulk of olfactory chemosensory event-related potentials consist of a negative component \((N1)\) occurring between 320 and 450 ms after stimulus onset, followed by a positive \((P2)\) component occurring between 530-800 ms (Hummel et al., 1992; Hummel et al., 2003; Hummel and Kobal, 1999, 2002; Rombaux et al., 2006).

In cases of chronic rhinosinusitis, both orthonasal and retronasal scores can be decreased, with scoring of both anosmia and hyposmia. Electrophysiological investigations show
abnormal responses with in moderate cases decreased amplitude and an increased latency and in severe cases the absence of olfactory responses (Rombaux et al., 2009). It is interesting to note that while in chronic rhinosinusitis, there is no difference between orthonasal and retronasal score, patients with CRS with polyps have a better retronasal than orthonasal score (Landis et al., 2003). Moreover ortho- and retronasal scores do not have a correlation when patient demonstrate an olfactory dysfunction related to sinonasal disease score proving that ortho- and retronasal scores have a distinct evolution in such cases (Rombaux et al., 2008).

5. Imaging of the olfactory apparatus in CRS

The MRI is the imaging modality of choice for the evaluation of the olfactory apparatus since it allows examining the olfactory bulb, olfactory tract and central olfactory projection areas. The assessment of olfactory bulb volume is particularly useful in the evaluation of olfactory disorder associated with CRS. Rombaux et al. (2008) demonstrated that the olfactory bulb volume is correlated with the sinonasal disease score, and patients having a sinonasal disease score \( \geq 12 \) significantly have larger olfactory bulb volume than patients with higher score. Smaller olfactory bulb volume is thus associated with a higher degree of sinonasal pathology. On contrast the olfactory function of the patients assessed with psychophysical testing was only slightly decreased or was even normal, emphasizing the idea that the olfactory bulb volume changes are more sensitive to subtle changes in the olfactory system than results of psychophysical testing. (Figure1)

![Fig. 1. T2-MRI on the coronal place of patient suffering from CRS (A) and control subject (B). Note that the olfactory bulb (white arrow) of the patient seems smaller than the OB of the control subject.](www.intechopen.com)

CT scan can also be useful in the assessment of patients with olfactory dysfunction associated with CRS. Litvack et al. (2009a) have shown that the severity of quantitative olfactory disorder is associated with the importance of the sinonasal disease and that mean CT score is significantly higher in patients with hyposmia and anosmia than in normosmic patient. It was also demonstrated that the opacification of the olfactory cleft has a negative correlation with the olfactory function in patients with CRS and that it is significantly correlated with the postoperative olfactory results; patients with mild opacification having...
better postoperative results than patients with moderate and severe anterior olfactory cleft result (Kim et al., 2011).

Fig. 2. CT-Scan in the coronal plane of a patient suffering from quantitative olfactory disorder. We can note on this picture an opacification of the olfactory cleft (white arrow) whereas there is no obvious rhinosinusitis. This image represents a so-called “olfactory cleft disease”.

6. Predictors of olfactory dysfunction in patients with CRS

As we discuss previously, it is agreed that the severity of olfactory dysfunction is related to the importance of the sinonasal disease (Litvack et al., 2008, 2009a) and that the mean endoscopy and mean CT score are significantly higher in patients with hyposmia and anosmia than in normosmic patients (Litvack et al., 2009a).

But common comorbidities have also been incriminated as severity factors of olfactory loss related to the CRS. Some authors have incriminated age of patients, smoking status, nasal polyposis, asthma, allergic rhinitis, previous endoscopic sinus surgery, septal deviation and inferior turbinate hypertrophy to cause olfactory dysfunction but the results are conflicting (Apter et al., 1999; Damm et al., 2003; Doty and Mishra, 2001; Kimmelman, 1994; Litvack et al., 2008; Simola and Malmberg, 1998). Nevertheless, the majority of authors agree that the age of patients and the presence of nasal polyps are predictors of olfactory dysfunction in CRS (Apter et al., 1999; Doty and Mishra, 2001; Litvack et al., 2008; Simola and Malmberg, 1998). Nasal polyposis is a significant predictor of olfactory dysfunction and it has been showed that there is a negative correlation between the size of the nasal polyps and the olfactory performance. Also, in patients with nasal polyposis, the blood eosinophilia seems to be correlated with subjective smell reduction (Hox et al., 2010).
On contrast, studies agree that semi-objective olfactory testing are not correlated with disease-specific or general health-related quality of life instruments (Litvack et al., 2009a; Hox et al., 2010)

7. Effects of treatment on olfactory function

7.1 Medical therapy and smell dysfunction

Only a few clinical studies have been conducted dealing with the improvement of olfactory function as a primary outcome in sinonasal disease treatment. Clinical trials of medical treatment for smell disorders associated with CRS have evaluated the efficacy of nasal and oral corticosteroid treatment, but we found no studies about other treatments that are currently used in the treatment of CRS (antileukotrienes, antihistamines,…).

Corticosteroids with their potent anti-inflammatory effects are admitted to be the standard treatment for olfactory disorders induced by CRS. Their action mechanism on olfactory function might be explained by an inhibition of the release of proinflammatory mediators (i.e. cytokines, adhesion molecules, mast cells, basophiles, eosinophiles) and a reduction in mucosa swelling (Demoly, 2007; Mygind et al., 2001).

Following EPOS recommendations, nasal steroids are recommended as the first line treatment for CRS with or without nasal polyps (Fokkens et al., 2007). Studies have evaluated the efficacy of different topical corticosteroids such as Betamethasone, Flunisolide, Mometasone Furoate, Fluticasone Propionate, Budesonide, Beclomethasone. Studies show that these drugs appear to be highly effective for most of the symptoms associated with CRS, including smell disorder, with a rapid onset of action and a cumulative effect after several days of use. In addition, they have the advantage of being a local therapy with limited side effects. Nevertheless the improvement in olfaction is frequently transient and incomplete (Blomqvist et al., 2003; Golding-Wood et al., 1996; Hellings and Rombaux, 2009; Lildholdt et al., 1995; Mott et al., 1997; Stuck et al., 2003).

Oral steroids are recommended in the treatment of CRS with nasal polyps as a second line treatment (Fokkens et al, 2007). Several studies have investigated the efficacy of oral steroids in patients with CRS with or without polyps. They have shown that these potent anti-inflammatory drugs increase the olfactory function and they appear to be more effective than nasal steroids (Heilmann et al., 2004; Vaidyanathan et al., 2011). Moreover, an initial oral steroid therapy followed by topical steroid therapy seems to be more effective than topical steroid therapy alone (Vaidyanathan et al., 2011). Nevertheless oral steroids have important side effects if they are frequently administrated or if their administration is prolonged. Bonfils et al. (2006) evaluated the risk of oral steroid treatment in patients with CRS with nasal polyps and showed that almost 50% of patients who received more than three short courses of oral steroid treatment had an asymptomatic adrenal insufficiency. Oral corticosteroids should thus be prescribed only if necessary and should be avoided if possible.

7.2 Surgical therapy and smell dysfunction

Functional endoscopic sinus surgery (FESS) is widely accepted as a treatment for chronic rhinosinusitis with or without nasal polyps after failure of the medical therapy.
The only randomized study to attempt comparison between steroid therapy and polypectomy showed significant improvement of subjective and objective olfactory function in both groups, remaining for one year. However these results should be tempered by the fact that the smell evaluation methodology was not described (Lildholdt, 1989)

Several studies have investigated the effect of FESS on olfactory function (for a review see Bonfils et al., 2009). Nevertheless the literature shows that there are major variations in the selection of patients for the surgery and some studies have poor validity because of poorly defined patient groups, lack of clear inclusion or exclusion criteria, poor description of the surgical procedure and poor description of the olfactory evaluation tool.

In this literature, olfactory function was assessed either by subjective patient self-reported olfactory function or by semi-objective olfactory testing (i.e. UPSIT). Considering patients self reported olfactory function, authors agree that FESS lead to a significant improvement of olfactory dysfunction. Park et al. (1998) showed that olfactory disturbance was reported in 72% of patients with CRS with or without polyps or recurrent acute rhinosinusitis preoperatively compared with 38% following FESS. Lund and Mac Kay (1994) also reported that 79% of patients reported improved olfaction after FESS. Klossek et al. (1997) reported a series of patients with nasal polyposis. 100% of patients had anosmia pre-operatively while after surgery 78% of patients recovered the sense of smell. Levine et al. (1990) reported a series of 250 patients with CRS with or without nasal polyps and noted only 16% of patients complaining of smell disturbance before surgery and 3% patients reporting anosmia after a mean follow-up of one year after surgery. Jakobsen and Svendstrup (2000) reported a series of 237 patients with CRS with or without nasal polyps. Anosmia was present in 48% of the patients with nasal polyps before surgery against 21 % after surgery. Only few studies have investigated the effect of FESS on olfactory function by using semi-objective olfactory testing. They have also shown that FESS as a significant positive effect on olfactory function. For examples, Lund and Scading (1994) evaluated olfactory function of patients with CRS using UPSIT and showed significant UPSIT score improvement after surgery. Downey et al. (1996) also used UPSIT to assess the olfactory function of patients with CRS pre- and post-operatively and showed that after surgery, 52% of patients had higher UPSIT score. Min et al. (1995) tested olfactory thresholds to butanol in patients with CRS. Before surgery, 33 % of patients had anosmia and 45% of patients had hyposmia. After surgery these percentages were 16% and 46% respectively. Delank and Stoll (1998) noted a post operative improvement of olfactory function assessed by olfactory thresholds and discrimination in 70% of patients with CRS. Klimek et al. (1997) reported improved odor identification and discrimination score after FESS in patients with CRS with nasal polyps. Hence, FESS seems to significantly improve olfactory function in patients with CRS with or without polyps.

Gudziol et al. (2009) explored the influence of the treatment of CRS on the olfactory function. They measured olfactory bulb volume and olfactory function of patients suffering from CRS before treatment and 3 months after. They showed that the olfactory bulb volume significantly increases after treatment and that the increase of olfactory bulb volume correlated significantly with an increase in odor thresholds.

Some authors have also studied the correlation between the severity of CRS and surgical outcomes on olfaction. It was reported that the improvement after FESS is significantly better in patients with severe olfactory dysfunction whereas it is not in patients with mild
olfactory dysfunction (Litvack et al., 2009b, Soler et al., 2010). The degree of nasal obstruction, the extent of the rhinosinusitis disease (evaluate by symptom score or CT scan), the coexistence of nasal polyps or allergic rhinitis do not predict the possibility of olfactory improvement after FESS (Bhattacharyya, 2006; Jiang et al., 2009; Wright and Agrawal, 2007). In addition, Jankowski et al. (Jankowski and Bodino, 2003) demonstrated that there was a correlation between the improvement of subjective olfactory function after oral corticosteroids given preoperatively and olfactory function 1 year after nasalisation.

Jankowski et al. (1997) compared the impact of different surgical approaches on olfactory function. Olfaction was evaluated by a 10-point visual analogue scale. They reported that improvement of olfaction was similar in both functional ethmoidectomy group and radical ethmoidectomy group six months after surgery. Nevertheless olfaction decreased in the functional ethmoidectomy group after six months while it was stable in the radical ethmoidectomy group.

8. Conclusion

CRS is the major cause of olfactory dysfunction among the population. The exact pathophysiology is this entity is still unclear. The olfactory dysfunction in these patients is reversible, as proved by the effect of treatments and MRI studies. Nevertheless, most studies show that the improvement of olfactory function is usually transient and incomplete. Different causes are hypothesized, but this is still a matter of debate. Future studies are necessary to better understand this entity.

9. References


www.intechopen.com


www.intechopen.com


Rhinosinusitis has both a great practical interest and a broad significance due to the scientific complexity of the pathogenetic problems related to the disease, not yet completely resolved, and their implications for clinical treatment. This book highlights certain specific topics that usually are not clarified in other resources. The first chapter is devoted to the impoverished quality of life experienced by patients suffering from rhinosinusitis. The second chapter focuses on the microbiological aspects of rhinosinusitis, while the two subsequent chapters explain the peculiar aspects of chronic rhinosinusitis and of recurrent chronic rhinosinusitis. The first chapter of the second section of the book is dedicated to the imaging techniques used to visualize the nasal sinuses and the other to a medical topical type of treatment.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
